# Curiosis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curiosis

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.curiosis.co.kr
- Total disclosed funding: $3.9M
- Latest round: Series B (Mar 26, 2019)
- Investors on record: 2

## About

Based in Seoul, South Korea, Curiosis Inc. is a biopharmaceutical company focused on innovative lab automation solutions and in vitro diagnostic medical devices, enhancing efficiency in research and healthcare environments.Curiosis Inc. specializes in advancing lab automation and diagnostic technologies. Founded in 2015 in Seoul, South Korea, the company has successfully completed 7 funding rounds. Most recently, in October 2024, Curiosis raised KRW 13 billion in a Pre-IPO round led by STIC Ventures, with participation from Kiwoom Investment, Shinhan Capital, and Timefolio Capital. The founder's background is not publicly documented, and there are no known changes in business strategy or operations since inception.Curiosis focuses on the biopharmaceutical sector, offering lab automation solutions and in vitro diagnostic medical devices. Key products include CurioAMD™ for automation optimization and CurioFactory™ for precision molding, which improve productivity in laboratories. The company serves various clients, including research institutions, hospitals, and diagnostic labs in North America, Europe, and parts of Asia, addressing challenges in cellular analysis and diagnostics.Curiosis generates revenue through direct sales of its imaging and automation products and partnerships with research institutions and healthcare providers. Transactions are primarily B2B, with clients purchasing tailored equipment and software solutions. While pricing details are not disclosed, flagship devices are positioned at a premium due to their advanced technology and the value they provide in diagnostic accuracy and operational efficiency.In October 2024, Curiosis Inc. secured KRW 13 billion in Pre-IPO funding to expand its production capabilities by enhancing its factory and automated equipment for synthetic biology research and development. The company aims to develop new products and increase its market presence, particularly targeting growth in North America and Europe within the next few years.

## Funding rounds

- Series B, Mar 26, 2019, $3.9M — AlpenRoute Asset Management, NewFlight

## Investors

- AlpenRoute Asset Management — Series B
- NewFlight — Series B